WASHINGTON - InterMune Inc. failed to win FDA approval of Esbriet (pirfenidone) as a treatment for a fatal lung disease, known as idiopathic pulmonary fibrosis (IPF), despite the strong backing of an agency panel of experts.

WASHINGTON - Shares of Acura Pharmaceuticals Inc. fell 32 percent Friday after an FDA advisory panel a day earlier refused to back approval of the firm's investigational pain drug Acurox (oxycodone HCl and niacin). (BioWorld Today)